Ivermectin — a drug once touted as a Covid treatment by conservatives — doesn’t improve recovery much, clinical trial finds

Ivermectin — a drug once touted as a Covid treatment by conservatives — doesn’t improve recovery much, clinical trial finds


Ivermectin, a drug once touted by conservatives as a treatment for Covid, does not meaningfully improve the recovery time for people with mild to moderate Covid-19, according a large clinical trial published in a peer-reviewed journal.

People who took ivermectin recovered from Covid in 12 days while people who didn’t take the drug recovered in 13 days, according to the study published in the Journal of the American Medical Association on Friday. Ivermectin has been approved to treat parasitic worms in humans, but it’s primarily used as a dewormer for horses.

“Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery,” the team of scientists led by Duke University School of Medicine wrote. “These findings do not support the use of ivermectin in patients with mild to moderate COVID-19,” they concluded.

Early on in the pandemic when there were few treatment options, ivermectin gained national notoriety when a couple groups of conservative doctors, including Front Line COVID-19 Critical Care Alliance and America’s Frontline Doctors began touting the drug on social media and elsewhere as a treatment for Covid. But there was little data backing up those claims and a study by Dr. Pierre Kory, a critical care physician in Wisconsin and president of the critical care alliance, claiming it was an effective treatment was later retracted for having flawed data.

The latest trial looked at 817 people who took ivermectin tablets for three days and compared them to 774 who received a placebo. The participants who took ivermectin received a daily dose based on their weight. Recovery from Covid was defined as three consecutive days without symptoms.

One person died in the ivermectin group while not one person who received the placebo passed away. The number of people hospitalized in each group was the same at nine participants each.

The study was conducted across 93 sites in the U.S. from June 2021 through May 2022 when the delta variant and then the omicron variant were dominant.

The Food and Drug Administration has not authorized ivermectin for treating or preventing Covid and has repeatedly warned people against taking the drug for anything other than its approved purpose.

Public interest in ivermectin spiked early in the pandemic when a lab study indicated that the drug slowed replication of the virus that causes Covid in a petri dish. But several trials have now found that the ivermectin does not provide any meaningful benefit for patients against Covid.

A study in the New England Journal of Medicine, published in May, found that ivermectin did not lower the risk of hospitalization from Covid.

Ivermectin is approved in the U.S. in a liquid or paste form to treat parasites in animals. There is also a tablet version that is FDA approved to treat parasitic worms, head lice and some skin conditions in people.

“There’s a lot of misinformation around, and you may have heard that it’s okay to take large doses of ivermectin. It is not okay,” the FDA says on its website, warning people that they could overdose.

The drug regulator also sternly warned people against taking ivermectin formulations designed for animals such as horses and cows.

“For one thing, animal drugs are often highly concentrated because they are used for large animals like horses and cows, which weigh a lot more than we do— up to a ton or more. Such high doses can be highly toxic in humans,” the FDA says.



Source

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Health

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]

Read More
OpenAI acquires health-care technology startup Torch
Health

OpenAI acquires health-care technology startup Torch

OpenAI has acquired the health-care technology startup Torch, the company announced on Monday. Torch was building a “unified medical memory” for artificial intelligence that aimed to bring a patient’s health data, which is typically siloed and stored across a number of different vendors and formats, into one place. Torch’s employees will join OpenAI as part […]

Read More
Thanks for your support, here’s how to connect with us
Health

Thanks for your support, here’s how to connect with us

When Becky Quick announced the CNBC Cures initiative, our effort to raise awareness for rare diseases and improve the lives of the 30 million people living with them, we knew the response would be big. We didn’t know it would be this big. The response has been amazing, overwhelming and humbling. Thank you for your interest — […]

Read More